FGF2 and cancer: As bFGF is a prominent factor in anti-VEGF therapy resistance, experimental evidence suggests that targeting bFGF in addition to VEGF may provide synergistic outcome and prove beneficial for the treatment of angiogenesis-related diseases, including cancer.